ProQR Therapeutics N.V. Begins Enrollment for PQ-010-001 Study

Comments
Loading...
ProQR Therapeutics N.V.(PRQR) says enrollment has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, an investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the DF508 mutation.
PRQR Logo
PRQRProQR Therapeutics NV
$1.994.19%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum38.59
Growth94.92
Quality-
Value47.13
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: